ARS Pharmaceuticals (SPRY) Net Income Growth (3y) (2023 - 2026)
ARS Pharmaceuticals (SPRY) Net Income Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 47.10% |
| 10 | ARS Pharmaceuticals | 569.96 Mn | 368.99 Mn | - | 86.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.55% |
| Dec 31, 2025 | -42.36% |
| Sep 30, 2025 | -95.35% |
| Jun 30, 2025 | -154.18% |
| Mar 31, 2025 | -47.65% |
| Dec 31, 2024 | 0.05% |
| Sep 30, 2024 | -51.81% |
| Jun 30, 2024 | 22.70% |
| Mar 31, 2024 | -67.61% |
| Dec 31, 2023 | 9.49% |
| Sep 30, 2023 | -1,120.29% |
| Jun 30, 2023 | -1,673.18% |
| Mar 31, 2023 | -1,811.87% |